BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31795962)

  • 1. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
    Alves WEFM; Bonatelli M; Dufloth R; Kerr LM; Carrara GFA; da Costa RFA; Scapulatempo-Neto C; Tiezzi D; da Costa Vieira RA; Pinheiro C
    BMC Cancer; 2019 Dec; 19(1):1173. PubMed ID: 31795962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.
    Pinheiro C; Sousa B; Albergaria A; Paredes J; Dufloth R; Vieira D; Schmitt F; Baltazar F
    Histol Histopathol; 2011 Oct; 26(10):1279-86. PubMed ID: 21870331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors.
    Pinheiro C; Granja S; Longatto-Filho A; Faria AM; Fragoso MC; Lovisolo SM; Lerário AM; Almeida MQ; Baltazar F; Zerbini MC
    Oncotarget; 2015 Dec; 6(42):44403-21. PubMed ID: 26587828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
    Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
    Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of metabolism-related proteins in phyllodes tumors.
    Kwon JE; Jung WH; Koo JS
    Tumour Biol; 2013 Feb; 34(1):115-24. PubMed ID: 22986897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
    Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
    Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.
    Aomatsu N; Yashiro M; Kashiwagi S; Kawajiri H; Takashima T; Ohsawa M; Wakasa K; Hirakawa K
    BMC Cancer; 2014 Jun; 14():400. PubMed ID: 24893880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
    Topcu TO; Ozdemir F; Kavgaci H; Gunaldi M; Kocoglu H; Imamoglu GI; Mentese A; Yaman SO; Orem A; Aydin F
    J Cancer Res Ther; 2018; 14(3):608-613. PubMed ID: 29893327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically relevant HIF-1α-dependent metabolic reprogramming in oropharyngeal squamous cell carcinomas includes coordinated activation of CAIX and the miR-210/ISCU signaling axis, but not MCT1 and MCT4 upregulation.
    Sáenz-de-Santa-María I; Bernardo-Castiñeira C; Secades P; Bernaldo-de-Quirós S; Rodrigo JP; Astudillo A; Chiara MD
    Oncotarget; 2017 Feb; 8(8):13730-13746. PubMed ID: 28099149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
    Janning M; Müller V; Vettorazzi E; Cubas-Cordova M; Gensch V; Ben-Batalla I; Zu Eulenburg C; Schem C; Fasching PA; Schnappauf B; Karn T; Fehm T; Just M; Kühn T; Holms F; Overkamp F; Krabisch P; Rack B; Denkert C; Untch M; Tesch H; Rezai M; Kittel K; Pantel K; Bokemeyer C; Loibl S; von Minckwitz G; Loges S
    Int J Cancer; 2019 Aug; 145(3):857-868. PubMed ID: 30694523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.
    Chen CL; Chu JS; Su WC; Huang SC; Lee WY
    Virchows Arch; 2010 Jul; 457(1):53-61. PubMed ID: 20526721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells.
    Ames S; Andring JT; McKenna R; Becker HM
    Oncogene; 2020 Feb; 39(8):1710-1723. PubMed ID: 31723238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycolysis-related protein expression in thyroid cancer.
    Nahm JH; Kim HM; Koo JS
    Tumour Biol; 2017 Mar; 39(3):1010428317695922. PubMed ID: 28347233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma.
    Schuurbiers OC; Meijer TW; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; van der Drift MA; van der Heijden EH; Oyen WJ; Visser EP; Span PN; Bussink J
    J Thorac Oncol; 2014 Oct; 9(10):1485-93. PubMed ID: 25170642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype.
    Sousa B; Ribeiro AS; Nobre AR; Lopes N; Martins D; Pinheiro C; Vieira AF; Albergaria A; Gerhard R; Schmitt F; Baltazar F; Paredes J
    BMC Cancer; 2014 Oct; 14():734. PubMed ID: 25269858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
    Brown-Glaberman U; Marron M; Chalasani P; Livingston R; Iannone M; Specht J; Stopeck AT
    Dis Markers; 2016; 2016():9810383. PubMed ID: 26941473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.
    Pinheiro C; Miranda-Gonçalves V; Longatto-Filho A; Vicente AL; Berardinelli GN; Scapulatempo-Neto C; Costa RF; Viana CR; Reis RM; Baltazar F; Vazquez VL
    Cell Cycle; 2016 Jun; 15(11):1462-70. PubMed ID: 27105345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Goorts B; van Nijnatten TJ; de Munck L; Moossdorff M; Heuts EM; de Boer M; Lobbes MB; Smidt ML
    Breast Cancer Res Treat; 2017 May; 163(1):83-91. PubMed ID: 28205044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.